Previous 10 | Next 10 |
Gainers: Scienjoy (SJ) +48%.Second Sight Medical Products (EYES) +36%.Greenwich LifeSciences (GLSI) +32%.Brooklyn ImmunoTherapeutics (BTX) +31%.Romeo Power (RMO) +28%.Target Hospitality (TH) +27%.BBQ Holdings (BBQ) +27%.SELLAS Life Sciences (SLS) +22%.GT Biopharma (GT...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 30, 2021 – Cancer research and development are a major part of the biotechnology industry, and there is always room for improvement and growth. Recently, biotech company Perimete...
SELLAS Life Sciences (SLS): FY GAAP EPS of -$2.11 misses by $0.28.Revenue of $1.9MCash and cash equivalents of $35.3M.Shares +5.2%.Press Release For further details see: SELLAS Life Sciences EPS misses by $0.28
Entered into Exclusive License Agreement, with $7.5 Million Upfront License Fee and Potential to Receive up to an Additional $194.5 Million, with 3D Medicines for Development and Commercialization of Galinpepimut-S in China; Additional $1 Million Milestone Triggered in February 2021 ...
This continues our series on busting options myths where we explore a different way to sell options. In this article, we discuss myths around selling puts. These myths generally teach: (i) only sell puts on companies you wouldn't mind owning; (ii) selling puts requires a neutral t...
We propose a method for selling options that defies many myths around options selling. We analyzed options prices using statistical modelling and calculus to improve the "expected value" of trading versus conventional principles. Trades based on the criteria below are likely to wi...
Gainers: Tyme Technologies (TYME) +110%, GW Pharmaceuticals (GWPH) +47%, Zynerba Pharmaceuticals (ZYNE) +39%, SELLAS Life Sciences (SLS) +38%, InMed Pharmaceuticals (INM) +15%.Losers: Vaxart (VXRT) -51%, Moleculin Biotech (MBRX) -26%...
The clinical-stage biopharmaceutical company SELLAS Life Sciences Group (SLS) has surged ~43.0% in the premarket trading after more than a dozen of Reddit posts discussed the stock in the past 24 hour period.Though none were popular, with most having upvotes in the low double- or si...
SELLAS Life Sciences (SLS) +60%.Tyme Technologies (TYME +57% as the company granted U.S. patent claims covering use of TYME-19.10X Capital Venture Acquisition (VCVCU +48% on plans to take Israeli electric-vehicle technology company REE Automotive public through a merg...
- Phase 3 REGAL Study of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Patients Underway in United States and Europe - - License Agreement with 3D Medicines for Development and Commercialization of GPS in China Initiates Commercialization Strategy for GPS ...
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
SELLAS Life Sciences Group Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks SELLAS’ Second RPDD Following the Designation for ALL Received Last Month - -...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...